Microsatellite instability status determined by next‐generation sequencing and compared with PD‐L1 and tumor mutational burden in 11,348 patients

Microsatellite instability (MSI) testing identifies patients who may benefit from immune checkpoint inhibitors. We developed an MSI assay that uses data from a commercially available next‐generation sequencing (NGS) panel to determine MSI status. The assay is applicable across cancer types and does...

Descripción completa

Detalles Bibliográficos
Autores principales: Vanderwalde, Ari, Spetzler, David, Xiao, Nianqing, Gatalica, Zoran, Marshall, John
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2018
Materias:
Clinical Cancer Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5852359/
https://www.ncbi.nlm.nih.gov/pubmed/29436178
http://dx.doi.org/10.1002/cam4.1372

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5852359/
https://www.ncbi.nlm.nih.gov/pubmed/29436178
http://dx.doi.org/10.1002/cam4.1372

Ejemplares similares